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C.typc natriuretic peptide (CNP), a recently di¢overed natriureti¢ p~ptid¢, has a potent stimulator), effect on cyclic GMP (cGMP) formation in 
cultured mouse astrocytes, Prctreatment of astroeytcs with phorboi 12-myristatc 13-a~tate (PMA). an activ=:=r of protein kina~ C (PKC), 
attenuated CNP-induced cGM P responses in u do~-dcp=ndent manner, with a half-ma~¢imal inhibitory concentration o1"6 nM, whereas the inactive 
phorbol ester analog..l=-phorbol 12.13-didecanout¢, was without effect. In tile presence of staurosporin¢, a PKC inhibitor, tile inhibitory eff~t 
or PMA on CNP.stimulated cGM P production was rever=d. These results Sall~eSt that PKC is ;m inhibitory modulator ol'CNP-stimulat=d cGMP 
respons~ in aslroeytes and that CNP may interact with neuropeptides which qimulate PKC. 
Protein kinase C: C.type natriuretic ~ptide: Cyclic GMP: Astroeyt¢ 
I. INTRODUCTION 
C-type natriureti¢ peptide (CNP), a third natriuretic 
peptide, was recently identified in porcine brain [ l] .  It 
is present in 2 major endogenous forms, designated 
CNP-53 and CNP-22, containing 53 and 22 amino 
acids, respectively, the former carrying the bioactive 
CNP-22 ~quence at its C-terminus [2.31. CNP has a 
highly conserved amino acid sequence acros~ different 
species, human CNP.22 being identical to rat and por- 
cine CNP-22 [4,5]. CNP-22 also shows sequence homol- 
ogy to atrial (ANP) and brain (BNP) natriuretic pep- 
:ides and exerts imilar, though less potent, pharmacol- 
ogical effects in regard to natriurcsis, diuresis and hypo. 
tensive activity [1]. 
CNP is present in high concentrations in the central 
nervous ystem (CNS) but not peripheral tissues [3,6,7]. 
In the rat, CNP mRNA is espressed only in the brain 
[4]. These findings suggest that CNP may function 
mainly as a neuropeptide. The CNS actions of CNP 
remain to be defined, although Samson et ai. [8] have 
shown recently that, in contrast to ANP, the intracer¢- 
broventricular injection of CNP-22 can stimulate a 
drinking response in the rat. 
Our group and others have recently demonstrated 
that CNP, like ANP and BNP, stimulates cyclic GMP 
(cGMP) production in cultured mouse astrocytes and 
rat gli~ma cells, Furthermore, CNP is several-fold more 
potent han AN P and BNP in stimulating cGM P forma- 
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tion in these ~ ih  [9,10]. The protein kinase C (PKC) 
family ofenzymes arc particularly abundant in the CNS 
and are important for such cellular processes as ion 
conductance, cell proliferation and cell differentiation 
[l 1-13], Distinct isoforrns of  PKC have lately bccn iden- 
tified in different ypey of glial cells and may mediate 
various functions within these cells [14]. We have there- 
fore investigated the possible interaction between PKC 
and CNP-depcndcnt cGMP respons:s in primary cul- 
tures o1" mouse astrocytcs. 
2, MATERIALS AND METHODS 
C-type natriuretl¢ I~ptid¢ (CNPt,=:) was purchascA from Peninsula 
(USA). Phorbo112-myristatc 13.acetate (PMA). phorbo112.13.dibu. 
tyrat¢ (PDBu). 4a.phorbol 12.13-didecanoate (,~PDD). 3.isobutyl.I. 
methylxanthin¢ {IBM:K). HEPES, and bovine r~rum albumin (BSA) 
were pureha~d from Situna (USA). Staurosporine was from Calbio- 
them (USA). The cGMP radioimmunoassay kit was from Amersham 
International (UK), 
Primary cuhurcs of mouse .~strocytes were prepared in 3S.mm- 
diameter cuhurc dishes usinB the method described by Hertz et al. [I 5] 
with son~c modifications [16.17]. Regular monitoring with indirccl 
immunofluor~c~nce using anti.glial fibrillary acidic protein (GFAP) 
anli~rum showed that approximately 95% of the cells were GFAP 
po~itiw?. 
Each exl~riment was ~rform~ in dupli~te or triplicate at 22t'C 
and repcatc.d three tinles, The concentrations given For the various 
rcugcnt,~ arc final concentrations, the total volume of incubation being 
I ml, "re s~udy the intluencc el' phorbol esters on CNP.depcndent 
¢GMP generation, monolayer astrocytes in 35.ram.diameter culture 
dishes were washed twic~ with buffer containing 5 /I BSA and l0 mM 
HEPE$ in serum.f r= minimal essential medium (pH 7.3), then incu- 
bated with varying con~ntrations f phorbol esters in buffer supple- 
mcntcd with I mM ol'th¢ phosphodiestcra=~ inhibitor IBMX at 22"C 
For I h. Following prcincubation, l0 nM CNP was added to mouse 
a,,tro=ylcs for l0 rain, tile time taken for CNP to achieve maximum 
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stimulation ofcGMP [10], The incubation w,s terminated by aspira|. 
ing the solution and rinsinl¢ the ¢¢1h with 2 ml of ice-cold phosphate. 
haltered saline, lmmcellul,tr ¢GMP was rel¢=tsed with i ml 6% (w/v) 
trichloroaceti¢ ~id (TCA). which was sub~q~ntly rentov~d by ~.  
traction with wutcr.,mturated iethyl ether. F~iiowingacetyhttion (18], 
cGMP in the ~mple wa~ measured by radioimmuno;tssay [17}. 
To ¢xami.e po~ibl~ ant-l~onism by stuurospnrine, aPRC inhibitor. 
on CNP.induced cGMP production, astro¢ytes were incul~tt~ with 
I00 aM stuurosporine in butter supplemented with 1 mM IBM~K at 
22"C for 15 rain, Incubation was continued for another hoar in the 
prcncn¢~ or ab~nc¢ of I0 nM PMA, followed by th¢ addition of 10 
nM PMA, followed by the addition or i0 nM CNP for 10 rain and 
sab~quent determination of  cGMP levels. 
Statiitical zmal~is was performed with 2.way ANOVA and Dun- 
news t-test for multiple comparir~ns, Statizaical signilicanc~ was 
taken as P < 0,05, 
3. RESULTS 
Preliminary experiments showed that pre-incubazion 
ofastrocytes with 1/.tim PMA for times panning 15 rain 
to 7 h progressively suppressed the CNP-induced incre- 
ment ofcGMP up to 2 h. The longer periods of incub:t. 
zion did not produce any furtlaer change in th0 incr~- 
mental cGMP response (data not shown), Subsequent 
doze-response experiments with phorbol esters were 
therefore conducted using a l-h preincubation time, 
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FiB, l, Dose-dependent inhibition of CNP-~timulat'~l cyclic GMP 
production by PMA in primary cultures of mouse astrocytes. Cells 
were treated with various con~ntmtions of PMA for I h. then exposed 
to 10 nM CNP for l0 rain. Following incubation, cOMP was released 
with 6% TCA and quantified as descritmd in section 2, Data arc reran 
• *" S.E.M. values of 6 data points derived from duplicate d=terlnma, 
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Fill. 2. Effect of pherbol ester analollU~ on CNP.sthuulated ¢OMP 
~neration in prim,ry eulture~ of mouse attr~:yt~, Exp~=rim¢ntal 
conditions were identical to tha',¢ in Fig, I and calls ware treated witl~ 
three concentrations of PDi~u and =PDD prior t~ exposure to l0 nM 
CNP, Control (Ctrl) ~mplcs were incubated with 10 nM CNP in the 
ab~nc¢ or pherbol esters. Results are mean ± S.E,M, of duplicate 
determinations from three separate xperiments. NS = not statistically 
sillniflcant. 
CNP stimulated cGMP production vigorously from a 
basal value of l.l .+. 0.1 pmol/mg protein to 80.7 +_ 8,2 
pmol/mg protein (mean ± S.E.M., n = 6) (Fig. l). Pro- 
treatment with PMA for l h had no effect on basal 
cGMP production, whereas PMA suppro~ed CNP- 
stimulated oGMP production i  a dose.dependent man- 
nor. with a half-maximal inhibitory concentration (lC~o) 
of 6 nM and mazimal inhibition of 22,3 ± 4,6 pmol 
cOMP/ms protein at l/.tM of PMA (Fig, l). Likewise, 
PDBu inhibited the CNP.induced cOMP response in a 
concentration-dependent manner. PDBu, at 10 aM, sig- 
nificantly suppressed the cOMP increment from 
74.6 ± 6.6 pmol/mg protein to 39.9 ± 2.7 pmol/mg pro- 
tein (P < 0.01), whereas ~zPDD, which does not stimu- 
late PKC. had no significant suppressive effect up to a 
concentration of l .uM (62,4 +_. 5,8 pmol/mg protein) 
(Fig. 2). 
In separate experiments incorporating staurosporine. 
10 nM PMA reduced CNP-d=p=ndent cGMP formation 
from 62,3± 3,9 to 32.9 ± 1.3 pmol/ms protein 
(P < 0,01), In th~ absence of PMA.  100 nM stauro. 
sporin¢ did not affect CNP-induced cGMP production, 
However. it blocked completely the PMA-mcdiated 
suppression of the CNP-stimulated cGMP response 
(Fig, 3). 
4. D ISCUSSION 
Our results indicate that CNP-induced cGMP pro- 
duction in astrocytes can be suppr=ss~ by the phorbol 
esters PMA and PDBu, both of which are activators of 
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Fil. 3, I~t'fccl of CNP, CNP plut PMA, CNP plus staurosporin¢ 4ST), 
or CNP plus staurosporine and PMA on OGMP formation in cultured 
mou~ astrocytes. Cells w~r¢ treated with either 100 nM staurosporin¢ 
or bufr~r alone for 15 rain, then incubated with tO nM PMA or buffer 
alo~ for l h before ~[msurc to I0 nM CNP, Results are mean ," 
S,E.M. of |hr~ experiments ~rformcd in duplicate, NS = not 
statistically fignilicant. 
PKC [19,20]. This is analogous to the inhibitory action 
of PMA on ANP-dependent cGMP production in rat 
adrcnocorticai carcinoma cells [21]. The role of PKC 
activation in mediating this effect is supported by 2 
other observations. First, ctPPD, an inactive phorbol 
ester analog that does not stimulate PKC [19], did not 
suppress CNP-induced cGMP respond. Secondly, stau- 
rosporine, a potent PKC inhibitor [22], blocked the in- 
hibitoW action of PMA. It is known that CNP acts 
upon an isoform of rec.¢ptor guanylate cyclase (GC-B). 
which consists of 4 domains [23,24]. Attenuation of the 
CNP.indu~d cGMP response by PKC could be medi- 
ated by phosphorylation f receptor guanylate cyclase, 
leading to a decrease in CNP binding and/or suppres- 
sion of the activity of the kinas¢-lik© or catalytic do- 
main. 
Astrocyt¢ cGMP production, in response to 10 nM 
CNP. is attenuated, but not fully blocked, even with 
high doses of PMA and PDBu, suggesting that other 
regulatory mechanisms ust also be involved. In accord 
with this. PMA attenuates only moderately ANPMe- 
pendent cOMP responses in cultured vascular smooth 
muscle cells whereas the PKC-activating hormones 
vasopressin and angiotensin [I [25,26]. markedly inhibit 
cGMP ~lccumulation in these cells within 1 rain of incu- 
bation, an effect attributed to their ability to increase 
cytoplasmic free calcium by stimulating inositol phos- 
pholipid turnover [27]. Endothelln h~b also/:z~mt ~hown 
to inhibit ANP, augmente~a cGMP responycs in tiiial 
c©lls within 5 rain, possibly by alterin~ ~h¢ ~'~i~'ii~, of
kinases other than PKC [28]. However, a contributory 
effect of PKC activation with more prolonged incuba- 
tion with endothelin, a known PKC stimulator [29], 
cannot be excluded. Recently, Haneda et al. [30] bays 
reported that PKC activation is nec~sary for the sus- 
tained suppressive action of angiotensin lI on ANP- 
induced cGNIP production in slomerular mesangial 
cells, Sin¢¢ th¢se hormon~ also exist as neurolmptides 
[31,32], our findings, taken together with the observa- 
tions of others, rais¢ the possibility that a numtmr of 
neuropcptides may interact with CNP (in at least some 
instances through modulation of PKC) in the CNS. 
Work is c,r~nlly in progress to investigate this issue. 
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